Teva Pharma posts Q3 profit ahead of estimates; ups FY outlook

Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) posted third-quarter profit ahead of expectations and hiked its full-year 2015 forecast.

The company reported earnings of $1.35 per share excluding one-time items in compared with $1.33 a year ago.

Erez Vigodman, Teva's chief executive, said: “This was a transformative quarter for Teva as we continued to deliver on all financial, operational and strategic promises. We continue to focus efforts on our pending acquisition of Actavis Generics and the acquisition of Rimsa, while continuing to bolster our specialty pipeline, especially our late-stage assets, and further evolving our business model to position Teva for long-term, sustainable growth.”